ADVA
8.6.2022 09:02:06 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Partner Communications has deployed its Oscilloquartz timing technology to support 5G rollout throughout Israel. The solution provides the level of accuracy and availability needed for next-generation mobile services and time-sensitive low-latency applications. Featuring ADVA’s Oscilloquartz core grandmaster devices, enhanced primary reference time clock (ePRTC) technology and multi-band GNSS receivers, the new timing infrastructure is ultra-resilient and prepared to withstand the rising threat of jamming and spoofing attacks. ADVA’s partner RDT Equipment & Systems also played a significant role in the deployment, carrying out installation, configuration and troubleshooting. Together with ADVA, it will provide Partner Communication with ongoing maintenance and support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607006044/en/
“Upgrading a major nationwide mobile network like ours required the most advanced timing technology and the support of an expert team. That’s why we selected ADVA’s Oscilloquartz synchronization solution built on a core PTP grandmaster clock with full hardware redundancy and a scalable modular design. It offers many fan-out options, including PTP over multiple 10Gbit/s interfaces, and its advanced GNSS technologies ensure highest availability even under challenging conditions,” said Yigal Giladi, VP of engineering at Partner Communications. “With our new timing infrastructure, we can deliver the best possible mobile 5G experience to our customers. Now when GNSS is compromised or otherwise unavailable, ADVA’s ePRTC solution means we can still deliver phenomenally accurate timing across our network even during very long GNSS outages.”
Partner Communications’ new timing infrastructure features the OSA 5440 , a fully redundant, scalable, and modular multi-technology grandmaster for core deployment. Operating with the OSA 3230B ePRC cesium clock and OSA clock combiner, it provides an ePRTC system, providing high levels of time stability compliant with the ITU-T G.8272.1 standard. Onboard multi-band, multi-constellation receivers compensate for atmospheric disturbances to filter out timing errors. What’s more, centralized AI-powered GNSS assurance software identifies and protects against vulnerabilities of satellite-based timing. The solution also includes the OSA 5410 Series for continuous probing and assurance, enabling Partner Communications’ team to anticipate any issues and minimize disruption to service. The technology is remotely controlled by ADVA’s Ensemble Controller with Sync Director. This provides a powerful management platform, giving Partner Communications full visibility of its synchronization infrastructure and assuring accurate timing.
“Partner Communications has taken a major leap forward in terms of the accuracy and reliability of its synchronization network. Their team was determined to make their timing infrastructure the most precise and robust it could be, and so our engineers have worked tirelessly on design, testing and installation to ensure an end-to-end solution that delivers for Partner Communications’ customers now and for many years to come,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “This timing solution delivers a unique set of features to mitigate GNSS vulnerabilities, such as multi-band, multi-constellation receivers and AI-powered analytics. In a world of increasing jamming and spoofing attacks, this will prove invaluable for mobile users across Israel.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607006044/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
